Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum

Growth assets now comprise 58.2% of Bristol Myers Squibb Company's revenues, with the legacy portfolio also reporting a promising deceleration in top-line erosion cadence. The successful Opdivo/Qvantig conversion and the upcoming launches like iberdomide/mezigdomide target significant multiple myeloma market opportunities. The raised FY2026 guidance and productivity initiatives drive top-line/margin expansion, with the rich cash flows delivering a secure dividend and healthier balance sheet.

The recent breakout has contributed to moderated dividend yields, with interested investors recommended to buy upon a pullback to 100/200 DMAs to enhance total return. BMY remains a Great Buy, with the robust portfolio renewal and multi-year valuation re-rating underpinning the double-digit upside potential to my bull-case LTPT of $92.40.

I previously rated Bristol Myers Squibb Company (BMY) as a Buy in July 2026, as the management delivered a promising portfolio renewal cadence. In this article, I shall discuss why BMY remains a Great Buy, albeit preferably on a pullback.